Magazin
2010-01-21
Basel, Switzerland (ots/PRNewswire) - New data from twolarge studies observing the routine use of Avastin-based therapy inmore than 3,200 patients will be announced showing impressivetreatment benefits in a non-selected patient population. Key findingsincluded high rates of tumour shrinkage and overall survival beyond 2years when Avastin is combined with the most common chemotherapyregimens. The data will be presented at the ASCO GI congress inOrlando (22 - 24 January 2010).
Three Out of 5 Patients Experienced Tumour Shrinkage
- In a large, prospective German observational study, which included 1,620 patients, the average rate of tumour shrinkage (response rate) was 60% for Avastin combined with chemotherapy. Successfully reducing the size of metastatic lesions may increase the chance of having them surgically removed, which could lead to long term survival or even a cure.
Survival in Excess of Two Years, Consistent Across DifferentChemotherapy Regimens
In the same German study, median overall survival exceeded 25months. In the group of patients treated with oxaliplatin-basedchemotherapy, the most commonly used chemotherapy in this setting,median overall survival was 27 months. Historically, median overallsurvival with chemotherapy alone did not exceed 20 months.
A similarly sized (1,658 patients) observational study carriedout in the Czech Republic showed that elderly patients treated withAvastin combined with chemotherapy achieved similar results. Patientsover the age of 65 years had a median survival time of 29.5 months.Patients under 65 years old had a similar median survival of 29.3months.
"Since its introduction 5 years ago Avastin has changed the waymetastatic colorectal cancer is treated and has become a standard ofcare", said Niko Andre, Global Medical Director for Avastin. "Theseresults confirm survival in routine practice can now exceed 2 years,which is great news for patients."
In both studies Avastin's established side effect profile wasconfirmed and no new safety signals were identified.
About the German study
The German community-based study is a large prospectiveobservational cohort study that included 1,620 eligible patients,between January 2005 and June 2008, with previously untreatedmetastatic colorectal cancer. Patients in the study received Avastin,every 2 weeks, with various standard first-line chemotherapyregimens, the choice of which was at the physicians' discretion. Themajority of chemotherapy regimens selected were oxaliplatin oririnotecan based. Patients were observed for up to 4 years after theinitiation of treatment. Pre-defined efficacy endpoints were;response rate, PFS, and overall survival. Adverse events wererecorded and assessed as potentially related to treatment or assevere.
About the Czech study
The Czech study included 1,658 patients with previously untreatedmetastatic colorectal cancer who received Avastin, every 2 or 3weeks, in combination with various chemotherapy regimens betweenOctober 2005 and October 2009. The study aimed to determine possibledifferences in efficacy and safety of Avastin between the age groupsof <65 years and >65 years. In the study one-quarter of diagnosedpatients were 65 years of age or older. Patients received Avastincombined with chemotherapy at the physicians' discretion. The mostcommon chemotherapy partners for Avastin were XELOX, FOLFOX andFOLFIRI with oxaliplatin-based regimens being the most frequent withmore than 60%.
About Avastin
Avastin is an antibody that specifically binds and blocks VEGF(vascular endothelial growth factor). VEGF is the key driver oftumour angiogenesis - an essential process of development andmaintenance of blood vessels which is required for a tumour to growand to spread (metastasize) to other parts of the body. Avastin'sprecise mode of action helps control tumour growth and metastaseswith only a limited impact on side effects of chemotherapy.
Avastin has proven survival benefits across multiple tumourtypes. Avastin is approved in Europe for the treatment of theadvanced stages of four common types of cancer: colorectal cancer,breast cancer, non-small cell lung cancer (NSCLC) and kidney cancer.These types of cancer collectively cause nearly 3 million deaths eachyear. In the US, Avastin was the first anti-angiogenesis therapyapproved by the FDA and is now approved for the treatment of fivetumour types: colorectal cancer, non-small cell lung cancer, breastcancer, glioblastoma, and renal cell carcinoma.
More than 500,000 patients have been treated with Avastin so far.A comprehensive clinical programme with over 450 clinical trials isinvestigating the use of Avastin in various tumour types (includingcolorectal, breast, non-small cell lung, brain, gastric, ovarian,prostate and others) and different settings (advanced or early stagedisease).
About Roche
Headquartered in Basel, Switzerland, Roche is a leader inresearch-focused healthcare with combined strengths inpharmaceuticals and diagnostics. Roche is the world's largest biotechcompany with truly differentiated medicines in oncology, virology,inflammation, metabolism and CNS. Roche is also the world leader inin-vitro diagnostics, tissue-based cancer diagnostics and a pioneerin diabetes management. Roche's personalised healthcare strategy aimsat providing medicines and diagnostic tools that enable tangibleimprovements in the health, quality of life and survival of patients.
In 2008, Roche had over 80'000 employees worldwide and investedalmost 9 billion Swiss francs in R&D.
The Group posted sales of 45.6 billion Swiss francs. Genentech,United States, is a wholly owned member of the Roche Group. Roche hasa majority stake in Chugai Pharmaceutical, Japan. For moreinformation: http://www.roche.com.
All trademarks used or mentioned in this release are protected bylaw.
Additional information
- About cancer: http://www.roche.com/cancer.htm
- B-Roll and visuals can be found at:http://www.thenewsmarket.com
Annabel Entress Galliard Healthcare aentress@galliardhealth.com +44(0)-20-7663-2254 Dominic Elliston Galliard Healthcare delliston@galliardhealth.com +44(0)-7717-502-860 Sri Chaudhuri Roche Pharmaceuticals sriranjan.chaudhuri@roche.com +41(0)61-687-5104
ots Originaltext: Roche PharmaceuticalsIm Internet recherchierbar: http://www.presseportal.de
Contact:CONTACT: Annabel Entress, Galliard Healthcare, aentress@galliardhealth.com, +44(0)-20-7663-2254; Dominic Elliston, Galliard Healthcare,delliston@galliardhealth.com, +44(0)-7717-502-860; Sri Chaudhuri, RochePharmaceuticals, sriranjan.chaudhuri@roche.com , +41(0)61-687-5104
New Real World Avastin Data From Over 3,200 Metastatic Colorectal Cancer Patients Confirms Survival Benefit Beyond 2 Years
Basel, Switzerland (ots/PRNewswire) - New data from twolarge studies observing the routine use of Avastin-based therapy inmore than 3,200 patients will be announced showing impressivetreatment benefits in a non-selected patient population. Key findingsincluded high rates of tumour shrinkage and overall survival beyond 2years when Avastin is combined with the most common chemotherapyregimens. The data will be presented at the ASCO GI congress inOrlando (22 - 24 January 2010).
Three Out of 5 Patients Experienced Tumour Shrinkage
- In a large, prospective German observational study, which included 1,620 patients, the average rate of tumour shrinkage (response rate) was 60% for Avastin combined with chemotherapy. Successfully reducing the size of metastatic lesions may increase the chance of having them surgically removed, which could lead to long term survival or even a cure.
Survival in Excess of Two Years, Consistent Across DifferentChemotherapy Regimens
In the same German study, median overall survival exceeded 25months. In the group of patients treated with oxaliplatin-basedchemotherapy, the most commonly used chemotherapy in this setting,median overall survival was 27 months. Historically, median overallsurvival with chemotherapy alone did not exceed 20 months.
A similarly sized (1,658 patients) observational study carriedout in the Czech Republic showed that elderly patients treated withAvastin combined with chemotherapy achieved similar results. Patientsover the age of 65 years had a median survival time of 29.5 months.Patients under 65 years old had a similar median survival of 29.3months.
"Since its introduction 5 years ago Avastin has changed the waymetastatic colorectal cancer is treated and has become a standard ofcare", said Niko Andre, Global Medical Director for Avastin. "Theseresults confirm survival in routine practice can now exceed 2 years,which is great news for patients."
In both studies Avastin's established side effect profile wasconfirmed and no new safety signals were identified.
About the German study
The German community-based study is a large prospectiveobservational cohort study that included 1,620 eligible patients,between January 2005 and June 2008, with previously untreatedmetastatic colorectal cancer. Patients in the study received Avastin,every 2 weeks, with various standard first-line chemotherapyregimens, the choice of which was at the physicians' discretion. Themajority of chemotherapy regimens selected were oxaliplatin oririnotecan based. Patients were observed for up to 4 years after theinitiation of treatment. Pre-defined efficacy endpoints were;response rate, PFS, and overall survival. Adverse events wererecorded and assessed as potentially related to treatment or assevere.
About the Czech study
The Czech study included 1,658 patients with previously untreatedmetastatic colorectal cancer who received Avastin, every 2 or 3weeks, in combination with various chemotherapy regimens betweenOctober 2005 and October 2009. The study aimed to determine possibledifferences in efficacy and safety of Avastin between the age groupsof <65 years and >65 years. In the study one-quarter of diagnosedpatients were 65 years of age or older. Patients received Avastincombined with chemotherapy at the physicians' discretion. The mostcommon chemotherapy partners for Avastin were XELOX, FOLFOX andFOLFIRI with oxaliplatin-based regimens being the most frequent withmore than 60%.
About Avastin
Avastin is an antibody that specifically binds and blocks VEGF(vascular endothelial growth factor). VEGF is the key driver oftumour angiogenesis - an essential process of development andmaintenance of blood vessels which is required for a tumour to growand to spread (metastasize) to other parts of the body. Avastin'sprecise mode of action helps control tumour growth and metastaseswith only a limited impact on side effects of chemotherapy.
Avastin has proven survival benefits across multiple tumourtypes. Avastin is approved in Europe for the treatment of theadvanced stages of four common types of cancer: colorectal cancer,breast cancer, non-small cell lung cancer (NSCLC) and kidney cancer.These types of cancer collectively cause nearly 3 million deaths eachyear. In the US, Avastin was the first anti-angiogenesis therapyapproved by the FDA and is now approved for the treatment of fivetumour types: colorectal cancer, non-small cell lung cancer, breastcancer, glioblastoma, and renal cell carcinoma.
More than 500,000 patients have been treated with Avastin so far.A comprehensive clinical programme with over 450 clinical trials isinvestigating the use of Avastin in various tumour types (includingcolorectal, breast, non-small cell lung, brain, gastric, ovarian,prostate and others) and different settings (advanced or early stagedisease).
About Roche
Headquartered in Basel, Switzerland, Roche is a leader inresearch-focused healthcare with combined strengths inpharmaceuticals and diagnostics. Roche is the world's largest biotechcompany with truly differentiated medicines in oncology, virology,inflammation, metabolism and CNS. Roche is also the world leader inin-vitro diagnostics, tissue-based cancer diagnostics and a pioneerin diabetes management. Roche's personalised healthcare strategy aimsat providing medicines and diagnostic tools that enable tangibleimprovements in the health, quality of life and survival of patients.
In 2008, Roche had over 80'000 employees worldwide and investedalmost 9 billion Swiss francs in R&D.
The Group posted sales of 45.6 billion Swiss francs. Genentech,United States, is a wholly owned member of the Roche Group. Roche hasa majority stake in Chugai Pharmaceutical, Japan. For moreinformation: http://www.roche.com.
All trademarks used or mentioned in this release are protected bylaw.
Additional information
- About cancer: http://www.roche.com/cancer.htm
- B-Roll and visuals can be found at:http://www.thenewsmarket.com
Annabel Entress Galliard Healthcare aentress@galliardhealth.com +44(0)-20-7663-2254 Dominic Elliston Galliard Healthcare delliston@galliardhealth.com +44(0)-7717-502-860 Sri Chaudhuri Roche Pharmaceuticals sriranjan.chaudhuri@roche.com +41(0)61-687-5104
ots Originaltext: Roche PharmaceuticalsIm Internet recherchierbar: http://www.presseportal.de
Contact:CONTACT: Annabel Entress, Galliard Healthcare, aentress@galliardhealth.com, +44(0)-20-7663-2254; Dominic Elliston, Galliard Healthcare,delliston@galliardhealth.com, +44(0)-7717-502-860; Sri Chaudhuri, RochePharmaceuticals, sriranjan.chaudhuri@roche.com , +41(0)61-687-5104
Roche Pharmaceuticals Homepage ,Story,Pressemappe
| Preisvergleich Medikamente |
|
In Zusammenarbeit mit Medizinfuchs |
Tags bei Technorati: pharma
